{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:56:45Z","timestamp":1790038605488,"version":"4.0.1"},"reference-count":62,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Glioblastoma is known as the most aggressive primary brain tumor in adults, and it is still largely not curable, with a median survival of approximately 15 months when standard multimodal therapy is applied. The standard treatment nowadays is maximal safe surgical resection, associated with radiotherapy and temozolomide. Treatment effectiveness is limited not only by an impassable blood\u2013brain barrier (BBB) to drug delivery to the brain, but also by the heterogeneity of the tumors and intrinsic or acquired drug resistance, resulting in a certain and inescapable tumor relapse. Therefore, novel drug delivery systems are being designed to overcome the BBB and improve therapeutic efficacy. These approaches include nanoparticle-mediated delivery systems, convection-enhanced intra-tumoral infusion, implantable drug-releasing devices, and noninvasive focused ultrasound technology, which induced transient disruption of the BBB. These approaches are designed to enhance local drug exposure and reduce systemic toxicity with promising preclinical and early clinical results. However, many clinical and technical challenges remain, especially the need for safety, homogeneous drug delivery, and translation of these advances into effective clinical therapies. Current glioblastoma treatment landscape and opportunities include maturing delivery systems, novel therapeutic approaches, including targeted molecular therapies and immunotherapy, as well as personalized regimens. This multidisciplinary modality may have the capacity to help not only patients with GBM but others as well through a multimodal approach of targeted drug delivery and innovative therapy in the long run to improve clinical outcomes of GBM in patients.<\/jats:p>","DOI":"10.3390\/medsci14010073","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:30:47Z","timestamp":1770309047000},"page":"73","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Breaking Barriers: Advancements in CNS Drug Delivery for Glioblastoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1291-2879","authenticated-orcid":false,"given":"Nicole","family":"Al Fidawi","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile Z.","family":"Attieh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Baghdadi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chahine","family":"El Bekai","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0593-2660","authenticated-orcid":false,"given":"Safaa","family":"Sayadi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-2424","authenticated-orcid":false,"given":"Ghassan","family":"Nabbout","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Sahyoun","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7983-2090","authenticated-orcid":false,"given":"Hilda E.","family":"Ghadieh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Azar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-1619","authenticated-orcid":false,"given":"Frederic","family":"Harb","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Sciences, University of Balamand, Kalhat, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Nahirney, P.C., and Tremblay, M.E. (2021). Brain Ultrastructure: Putting the Pieces Together. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.629503"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1126\/science.329.5991.502","article-title":"Is Pharma Running Out of Brainy Ideas?","volume":"329","author":"Miller","year":"2010","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.2147\/IJN.S405454","article-title":"Therapeutic Potential of Nanomedicine in Management of Alzheimer\u2019s Disease and Glioma","volume":"18","author":"Anwar","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37437","DOI":"10.1038\/s41598-025-21272-3","article-title":"Modulation of the blood\u2013brain barrier permeability by patient-derived glioblastoma stem cell secretome","volume":"15","author":"Sica","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/17425247.2016.1200557","article-title":"Harnessing nanomedicine for therapeutic intervention in glioblastoma","volume":"13","author":"Gutkin","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5114\/wo.2014.40559","article-title":"Review Glioblastoma multiforme\u2014An overview","volume":"5","author":"Szmidt","year":"2014","journal-title":"Wsp\u00f3\u0142czesna Onkol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and Molecular Prognostic Review of Glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2016.09.034","article-title":"Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma","volume":"243","author":"Bastiancich","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mosteiro, A., Pedrosa, L., Ferr\u00e9s, A., Diao, D., Sierra, \u00c0., and Gonz\u00e1lez, J.J. (2022). The Vascular Microenvironment in Glioblastoma: A Comprehensive Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061285"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2021.01.012","article-title":"Frontiers in the treatment of glioblastoma: Past, present and emerging","volume":"171","author":"Janjua","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/20415990.2024.2415281","article-title":"Comprehensive insights into glioblastoma multiforme: Drug delivery challenges and multimodal treatment strategies","volume":"16","author":"Dhiman","year":"2025","journal-title":"Ther. Deliv."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hersh, A.M., Alomari, S., and Tyler, B.M. (2022). Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084153"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Du, R., Wang, C., Zhu, L., and Yang, Y. (2022). Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102236"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2025.2913","article-title":"Drug resistance in glioblastoma: Challenges, mechanisms and therapeutic strategies (Review)","volume":"24","author":"Durga","year":"2025","journal-title":"Mol. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Eckerdt, F., and Platanias, L.C. (2023). Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance. Cancers, 15.","DOI":"10.3390\/cancers15133458"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., L\u00f3pez-Blanch, R., Pineda, B., Guti\u00e9rrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., and Estrela, J. (2024). Glioblastoma Therapy: Past, Present and Future. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052529"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/pr.117.014944","article-title":"Current Challenges and Opportunities in Treating Glioblastoma","volume":"70","author":"Shergalis","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yasinjan, F., Xing, Y., Geng, H., Guo, R., Yang, L., Liu, Z., and Wang, H. (2023). Immunotherapy: A promising approach for glioma treatment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1255611"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12935-024-03331-3","article-title":"New insights into targeted therapy of glioblastoma using smart nanoparticles","volume":"24","author":"Ghaznavi","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13205-025-04378-3","article-title":"Breaking barriers: Exploring blood\u2013brain barrier crossing mechanisms with nanomedicine for effective glioma treatment","volume":"15","author":"Ali","year":"2025","journal-title":"3 Biotech"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pdpdt.2017.04.017","article-title":"Light source is critical to induce glioblastoma cell death by photodynamic therapy using chloro-aluminiumphtalocyanine albumin-based nanoparticles","volume":"19","author":"Davanzo","year":"2017","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/jms.jms_4_18","article-title":"Nanotechnology in oncology: A concern on its unwanted effects and ethics","volume":"32","author":"Yasri","year":"2018","journal-title":"J. Med. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/nop\/npab065","article-title":"Convection-enhanced delivery for high-grade glioma","volume":"9","author":"Kang","year":"2022","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.wneu.2021.05.050","article-title":"Convection-Enhanced Delivery and Principles of Extracellular Transport in the Brain","volume":"151","author":"Faraji","year":"2021","journal-title":"World Neurosurg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"vdad044","DOI":"10.1093\/noajnl\/vdad044","article-title":"Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma","volume":"5","author":"Sperring","year":"2023","journal-title":"Neuro-Oncol Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11060-024-04904-y","article-title":"A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma","volume":"172","author":"Narsinh","year":"2025","journal-title":"J. Neurooncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1038\/s41467-019-13198-y","article-title":"Flexible, sticky, and biodegradable wireless device for drug delivery to brain tumors","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2200013","DOI":"10.1002\/adtp.202200013","article-title":"Localized Drug Delivery Systems in High-Grade Glioma Therapy\u2014From Construction to Application","volume":"5","author":"Hauck","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.14791\/btrt.2022.0017","article-title":"Local Drug Delivery Strategies for Glioblastoma Treatment","volume":"10","author":"Cha","year":"2022","journal-title":"Brain Tumor Res. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s43018-020-00119-y","article-title":"GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision","volume":"1","author":"Wang","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11060-022-03974-0","article-title":"Focused ultrasound for the treatment of glioblastoma","volume":"157","author":"Roberts","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.ejso.2022.05.023","article-title":"Electrochemotherapy and immune interactions; A boost to the system?","volume":"48","author":"Bendix","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.diii.2022.09.009","article-title":"Irreversible electroporation and electrochemotherapy in oncology: State of the art","volume":"103","author":"Tasu","year":"2022","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2100978","DOI":"10.1002\/advs.202100978","article-title":"Electrotherapies for Glioblastoma","volume":"8","author":"Jenkins","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-11-0451","article-title":"Preclinical Validation of Electrochemotherapy as an Effective Treatment for Brain Tumors","volume":"71","author":"Iversen","year":"2011","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.2147\/IJN.S440405","article-title":"Synergistically Enhancing Immunotherapy Efficacy in Glioblastoma with Gold-Core Silica-Shell Nanoparticles and Radiation","volume":"18","author":"Chen","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus Radiotherapy\u2013Temozolomide for Newly Diagnosed Glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yaghi, N.K., and Gilbert, M.R. (2022). Immunotherapeutic Approaches for Glioblastoma Treatment. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020427"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40164-024-00512-8","article-title":"Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: A comprehensive review","volume":"13","author":"Shen","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The Microenvironmental Landscape of Brain Tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"91779","DOI":"10.18632\/oncotarget.21586","article-title":"Recurrent glioma clinical trial, CheckMate-143: The game is not over yet","volume":"8","author":"Filley","year":"2017","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","article-title":"A review of glioblastoma immunotherapy","volume":"151","author":"Medikonda","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Achar, A., Myers, R., and Ghosh, C. (2021). Drug Delivery Challenges in Brain Disorders across the Blood\u2013Brain Barrier: Novel Methods and Future Considerations for Improved Therapy. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121834"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Pinheiro, R.G.R., Coutinho, A.J., Pinheiro, M., and Neves, A.R. (2021). Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111654"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"121949","DOI":"10.1016\/j.biomaterials.2022.121949","article-title":"Exosomes based strategies for brain drug delivery","volume":"293","author":"Rehman","year":"2023","journal-title":"Biomaterials"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Abdelsalam, M., Ahmed, M., Osaid, Z., Hamoudi, R., and Harati, R. (2023). Insights into Exosome Transport through the Blood\u2013Brain Barrier and the Potential Therapeutical Applications in Brain Diseases. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040571"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd4793","article-title":"Two decades of new drug development for central nervous system disorders","volume":"14","author":"Kesselheim","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III Randomized Trial Comparing the Efficacy of Cediranib as Monotherapy, and in Combination with Lomustine, Versus Lomustine Alone in Patients with Recurrent Glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/imt.14.21","article-title":"Rindopepimut: A Promising Immunotherapeutic for the Treatment of Glioblastoma Multiforme","volume":"6","author":"Swartz","year":"2014","journal-title":"Immunotherapy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature23000","article-title":"Transcription elongation factors represent in vivo cancer dependencies in glioblastoma","volume":"547","author":"Miller","year":"2017","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/neuonc\/noq203","article-title":"Clinical trial end points for high-grade glioma: The evolving landscape","volume":"13","author":"Reardon","year":"2011","journal-title":"Neuro-Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10637-010-9569-1","article-title":"Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP","volume":"30","author":"Buckle","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/j.celrep.2019.02.063","article-title":"Modeling Patient-Derived Glioblastoma with Cerebral Organoids","volume":"26","author":"Linkous","year":"2019","journal-title":"Cell Rep."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Falco, J., Agosti, A., Vetrano, I.G., Bizzi, A., Restelli, F., Broggi, M., Schiariti, M., DiMeco, F., Ferroli, P., and Ciarletta, P. (2021). In Silico Mathematical Modelling for Glioblastoma: A Critical Review and a Patient-Specific Case. J. Clin. Med., 10.","DOI":"10.3390\/jcm10102169"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.canlet.2016.03.011","article-title":"Nanoparticles in radiation oncology: From bench-side to bedside","volume":"375","author":"Rancoule","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdx106","article-title":"Glioblastoma targeted therapy: Updated approaches from recent biological insights","volume":"28","author":"Touat","year":"2017","journal-title":"Ann. Oncol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/73\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:36:26Z","timestamp":1770309386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medsci14010073"],"URL":"https:\/\/doi.org\/10.3390\/medsci14010073","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}